Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An Irf2-expressing oncolytic virus changes the susceptibility of tumor to antitumor T cells and promotes promotes tumor clearance

ABSTRACT: According to our previous studies, IRF1-deficient (IRF1-KO) tumor cells showed significantly reduced tumor growth when injected in several syngeneic mouse models including the B16-F10 melanoma, indicating that tumor cells require IRF1 for sustained tumor progression. Depletion of CD8+ T cells or NK cells could restore tumor growth of IRF1-KO cells. In addition, we found that loss of IRF1 in tumor cells could decrease the IFNγ-induced expression of PD-L1. To examine if IRF1 can be a target for cancer immunotherapy, we attempted to comprehensively identify genes that are specifically regulated by IRF1 in tumor cells that contribute to the tumor progression and the suppression of immune surveillance. Our RNA-seq data suggest that IRF1 regulates not only the expression of immune inhibitory ligands, but also the production of class I MHC molecules.

ORGANISM(S): Mus musculus

PROVIDER: GSE261564 | GEO | 2024/03/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

An Irf2-expressing oncolytic virus changes the susceptibility of tumor to antitumor T cells and promotes promotes tumor clearance

Project description:An Irf2-expressing oncolytic virus changes the susceptibility of tumor to antitumor T cells and promotes promotes tumor clearance

| PRJNA1087454 | ENA

proteome analysis of Lung tissue of mice bearing B16-F10-luc-G5 melanoma tumor with sleep fragmentation and with or with out the asdmistration of GL-pp

Project description:Proteome analysis of Lung tissue of mice bearing B16-F10-luc-G5 melanoma tumor with sleep fragmentation and with or with out the asdmistration of GL-pp. The mice were randomly divided into 4 groups: control group in general condition with no further treatment (CON group), tumor group with the burden of B16-F10-luc-G5 cells (Tumor group), T+SF group with SF and the burden of B16-F10-luc-G5 cells (T+SF group), and GL-pp group with SF, tumor cells burden, and the administration of 80 mg/kg GL-pp (GL-pp group). B16-F10-luc-G5 cells (5 × 1000000 cells/100 µL per mouse) were injected into the mice through the tail vein. The lung tissue of T+SF group and GL-pp group were analyzed by the proteome.

2021-09-10 | PXD025171 | Pride

Opposing tumor cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in anti-tumor immunity

Project description:Type I interferons (IFN-I) and IFN- foster antitumor immunity by facilitating T cell responses. Paradoxically, IFNs may promote T cell exhaustion by activating immune checkpoints. The downstream regulators of these responses are incompletely understood. Herein, we describe how Interferon Regulatory Factor 1 (IRF1) orchestrates these opposing effects of IFNs. IRF1 expression in tumors blocked Toll-like receptor and IFN-I-dependent host antitumor immunity by preventing IFN stimulated gene (ISG) programs and effector programs in dendritic cells and T cells. In contrast, expression of IRF1 in the host, but not IRF3 or IFN-, was also required for antitumor immunity to wildtype and Irf1-/- tumors. Mechanistically, tumor cell IRF1 regulated major histocompatibility class I expression and bound uniquely or together with STAT1 at many ISGs, contributing to expression of immunosuppressive but not immunostimulatory ISGs. Overexpression of PD-L1 in Irf1-/- tumors only partially restored tumor growth, suggesting that the negative effects of tumor IRF1 on antitumor immunity are multifactorial. Thus, we identify tumor cell IRF1 expression as a previously unrecognized selective inhibitor of host IFN-I dependent antitumor immunity, while host IRF1 and IFN-I are critical drivers of antitumor immune responses.

2024-05-01 | GSE246923 | GEO

Identification of tumor membrane proteins

Project description:Identification of chemotherapy-treated B16-F10 tumor membrane proteins

2024-08-28 | PXD055424 |

Tumor-derived small extracellular vesicle PD-L1 impedes macrophage-mediated antibacterial immunity in preexisting malignancy

Project description:Tumor-derived small extracellular vesicles (TEVs) were reported to carry various immunosuppressive molecules regulating immune response. We previously reported that TEV could express PD-L1 to systematically inhibit CD8 T cell anti-tumor immunity. Here, we observed that TEV PD-L1 suppressed the phagocytosis and bactericidal capacity of macrophages against E. coli. To investigate the potential mechanisms behind the impaired phagocytosis further, we collected and purified exosomes from the melanoma cell line B16-F10 PD-L1 knockout (KO) or vector culture to challenge RAW264.7 cells. We used RNA sequencing to reveal the key functional associated molecules for inhibiting the phagocytosis-associated pathway.

2024-10-24 | GSE275997 | GEO

Serca2b inhibition aids T cell activation and selectively promotes tumor cell death

Project description:We found that T cells and tumor cells are differentially dependent on Atp2a2 for their survival. In fact, Atp2a2 KO T cells have increased function, whereas Atp2a2 KO tumor cells die. Thapsigargin is a drug that targets the protein product of Atp2a2: Serca2b. We found that in tumor cells, the SAGA complex transmits TG signals to induce tumor cell death, principally via Ccdc101.

2023-11-10 | GSE161209 | GEO

Transcriptome analysis of CD4+ T cells from spleen and MC38 tumor

Project description:It is now clearly established that immune system can affect cancer response to therapy. However, the influence of tumor microenvironment on immune cells is not completely understood. In this respect, alternative splicing is increasingly described to affect immune system biology. Here, we showed that tumor microenvironment, by increasing alternative splicing events, induced the expression of an alternative isoform of the IRF1 transcription factor in Th1 cells. Furthermore, we also shown, in both mice and humans, that IRF1 alternative isoform alters IRF1 full form transcriptional activity on Il12rb1 promotor, resulting in decreased IFN-? secretion in Th1 cells. Thus, IRF1-short isoform increases in tumor microenvironment and to prevent this isoform appearance could potentiate Th1 cell antitumor effect.

2021-04-27 | GSE134851 | GEO

PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance.

Project description:Engineered oncolytic viruses are used clinically to destroy cancer cells and have the ability to boost anticancer immunity. Phosphatase and tensin homolog deleted on chromosome 10 loss is common across a broad range of malignancies, and is implicated in immune escape. The N-terminally extended isoform, phosphatase and tensin homolog deleted on chromosome 10 alpha (PTEN?), regulates cellular functions including protein kinase B signaling and mitochondrial adenosine triphosphate production. Here we constructed HSV-P10, a replicating, PTEN? expressing oncolytic herpesvirus, and demonstrate that it inhibits PI3K/AKT signaling, increases cellular adenosine triphosphate secretion, and reduces programmed death-ligand 1 expression in infected tumor cells, thus priming an adaptive immune response and overcoming tumor immune escape. A single dose of HSV-P10 resulted in long term survivors in mice bearing intracranial tumors, priming anticancer T-cell immunity leading to tumor rejection. This implicates HSV-P10 as an oncolytic and immune stimulating therapeutic for anticancer therapy.

| S-EPMC6258708 | biostudies-literature

Transcriptome analysis of Th1 cells from spleen, lymph nodes, draining lymph nodes and B16-F10 tumor

2021-04-27 | GSE134853 | GEO

Effect of PTEN treatment on the subcutaneous tumor formation model of PTEN knockout B16F10 cells in C57BL/6J mice

Project description:PTEN treatment can affect the tumor growth of PTEN knockout B16-F10 cells in C57BL/6J mice，We hope to analyze the changes that occur in various cells in tumors through single-cell RNA sequencing.

2024-07-24 | GSE249052 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data